R Thomas Lumbers

List of Publications by Year
in descending order

21 papers	1,730 citations	840776 11 h-index	940533 16 g-index
24 all docs	24 docs citations	24 times ranked	3495 citing authors

#	Article	IF	Citations
1	Genome-wide association and Mendelian randomisation analysis provide insights into the pathogenesis of heart failure. Nature Communications, 2020, 11, 163.	12.8	466
2	The druggable genome and support for target identification and validation in drug development. Science Translational Medicine, 2017, 9, .	12.4	437
3	Evidence-Based Assessment of Genes in Dilated Cardiomyopathy. Circulation, 2021, 144, 7-19.	1.6	213
4	A chronological map of 308 physical and mental health conditions from 4 million individuals in the English National Health Service. The Lancet Digital Health, 2019, 1, e63-e77.	12.3	192
5	Shared genetic pathways contribute to risk of hypertrophic and dilated cardiomyopathies with opposite directions of effect. Nature Genetics, 2021, 53, 128-134.	21.4	155
6	Genetic and functional insights into the fractal structure of the heart. Nature, 2020, 584, 589-594.	27.8	86
7	Therapeutic Targets for Heart Failure Identified Using Proteomics and Mendelian Randomization. Circulation, 2022, 145, 1205-1217.	1.6	50
8	Integrating polygenic risk scores in the prediction of type 2 diabetes risk and subtypes in British Pakistanis and Bangladeshis: A population-based cohort study. PLoS Medicine, 2022, 19, e1003981.	8.4	24
9	Estimating the Effect of Reduced Attendance at Emergency Departments for Suspected Cardiac Conditions on Cardiac Mortality During the COVID-19 Pandemic. Circulation: Cardiovascular Quality and Outcomes, 2021, 14, e007085.	2.2	18
10	Transforming and evaluating electronic health record disease phenotyping algorithms using the OMOP common data model: a case study in heart failure. JAMIA Open, 2021, 4, ooab001.	2.0	18
11	Type 2 Diabetes, Metabolic Traits, and Risk of Heart Failure: A Mendelian Randomization Study. Diabetes Care, 2021, 44, 1699-1705.	8.6	18
12	A population†based study of 92 clinically recognized risk factors for heart failure: co†occurrence, prognosis and preventive potential. European Journal of Heart Failure, 2022, 24, 466-480.	7.1	14
13	Genetic and environmental determinants of diastolic heart function. , 2022, 1, 361-371.		12
14	The genomics of heart failure: design and rationale of the HERMES consortium. ESC Heart Failure, 2021, 8, 5531-5541.	3.1	11
15	Life-Time Covariation of Major Cardiovascular Diseases. Circulation Genomic and Precision Medicine, 2021, 14, e002963.	3.6	5
16	Do beta-blockers and inhibitors of the renin–angiotensin aldosterone system improve outcomes in patients with heart failure and left ventricular ejection fraction >40%?. Heart, 2019, 105, 1533-1535.	2.9	4
17	A genetic model of ivabradine recapitulates results from randomized clinical trials. PLoS ONE, 2020, 15, e0236193.	2.5	3
18	A genetic model of ivabradine recapitulates results from randomized clinical trials. , 2020, 15, e0236193.		0

#	Article	IF	Citations
19	A genetic model of ivabradine recapitulates results from randomized clinical trials. , 2020, 15, e0236193.		0
20	A genetic model of ivabradine recapitulates results from randomized clinical trials. , 2020, 15, e0236193.		0
21	A genetic model of ivabradine recapitulates results from randomized clinical trials. , 2020, 15, e0236193.		0